TG Therapeutics (TGTX) statistics

Analysts' price targets and ratings, ownership, short interest, trading figures and dates for TG Therapeutics, as the data feed reports them.

Analysts' mean target, 7 analysts
$69.43
10.7% above the price

The 7 analysts reported by the data feed have a mean price target for TG Therapeutics of $69.43, 10.7% above the $62.71 price (range $21.00–$86.00). 27.66% of the float was sold short as of Oct 30, 2026. Institutions hold 78.9% of the shares and insiders 7.6%. Source: Yahoo Finance, read Nov 18, 2026.

Key facts

Analysts' mean target
$69.43+10.7% vs price
Analysts
7
Short interest
27.66%of float, Oct 30, 2026
Short ratio
18.16 days
Institutions
78.9%
Insiders
7.56%
Beta
1.81

Figures read . Source: Yahoo Finance (quoteSummary: key statistics, financial data, recommendation trend, major holders, insider purchases, calendar events). Analysts' targets and ratings, ownership and short interest are the data feed's figures and can lag the filings and exchange reports they come from. Figures, not advice.

Analysts' consensus as reported by the data feed

7 analysts covering TG Therapeutics, as the data feed counts them. Price targets and ratings are other people's estimates — not facts about the company, and not advice. Distances are from the latest price the feed gave with these figures, $62.71.

Analysts' price targets for TG Therapeutics
Mean price target$69.4310.7% above the price (+10.7%)
Median price target$75.0019.6% above the price (+19.6%)
Highest target$86.0037.1% above the price (+37.1%)
Lowest target$21.0066.5% below the price (−66.5%)
Analysts with a target7

Ratings this month · 8 analysts

Strong buy 1(13%)Buy 6(75%)Strong sell 1(13%)
Analysts' ratings of TG Therapeutics this month, by rating
RatingAnalystsShare
Strong buy113%
Buy675%
Hold00%
Sell00%
Strong sell113%

The feed averages these to 1.5 on its scale of 1 (strong buy) to 5 (strong sell), which it labels “strong buy”.

Who owns TG Therapeutics

Ownership of TG Therapeutics
Held by institutions78.9%589 institutions; percent of shares outstanding
Held by institutions, of the float85.4%
Held by insiders7.56%percent of shares outstanding
Shares outstanding151.15M
Float133.49Mshares available to trade
Insiders' net purchases, six months+1.05K1 purchases (6.05K shares), 1 sales (5K shares)

Percentages are of shares outstanding unless the row says float. Insiders' net purchases are shares bought minus shares sold by insiders, as the data feed totals their reported trades.

Short interest as reported by the data feed

Shares sold short and not yet covered, as of Oct 30, 2026. Short interest is counted twice a month, so this is not today's figure.

Short interest in TG Therapeutics
Shares short28.77Mas of Oct 30, 2026
Percent of float27.66%shares short ÷ float
Percent of shares outstanding19.03%shares short ÷ shares outstanding
Short ratio (days to cover)18.16shares short ÷ average daily volume

TG Therapeutics short interest from FINRA, with its history

Trading figures

Trading figures for TG Therapeutics
Beta1.81movement against the market; 1 moves with it
52-week high$68.03
52-week low$26.76
Average volume, 3 months1.91Mshares a day
Average volume, 10 days2.58Mshares a day

Questions and answers

What is the analysts' price target for TG Therapeutics (TGTX)?

As reported by the data feed, the mean price target of the 7 analysts covering TG Therapeutics is $69.43, 10.7% above the latest price of $62.71. The highest target is $86.00 and the lowest $21.00. Targets are analysts' estimates, not facts about the company and not advice.

How do analysts rate TG Therapeutics stock?

Of the 8 ratings the data feed reports for the current month, 1 are strong buy, 6 buy, 0 hold, 0 sell and 1 strong sell.

How many TG Therapeutics shares are sold short?

As reported by the data feed, 28.77M shares were sold short, 27.66% of the float as of Oct 30, 2026. At the average daily volume that is 18.16 days to cover. Short interest is reported twice a month; it is not today's figure.

Who owns TG Therapeutics stock?

As reported by the data feed, institutions hold 78.9% of the shares (589 institutions) and insiders 7.6%. There are 151.15M shares outstanding, of which 133.49M are in the float.

How much does TG Therapeutics stock move with the market?

Its beta, as reported by the data feed, is 1.81: a beta above 1 means the share has tended to move more than the market, below 1 less. Over the past 52 weeks it traded between $26.76 and $68.03.

Cite this page

Funkfolio, “TG Therapeutics (TGTX) statistics: analyst targets and short interest”, data as of 18 November 2026. https://funkfolio.com/stock/TGTX/statistics

Underlying data: Yahoo Finance.